Ad Header



The Pulse of the Pharmaceutical Industry

U.S. Supreme Court rejects patent appeal over Cubicin drug

Written by: | | Dated: Tuesday, May 31st, 2016

The U.S. Supreme Court on Tuesday rejected Cubist Pharmaceuticals Inc’s bid to revive four patents for its antibiotic drug Cubicin, paving the way for rival Hospira Inc to introduce a generic version as soon as this year.

The high court left in place a November ruling by the U.S. Court of Appeals for the Federal Circuit upholding a lower court ruling invaliding four of five patents held by Merck & Co Inc-owned Cubist, which were challenged by Pfizer Inc-owned Hospira.


(Reporting by Lawrence Hurley; Editing by Will Dunham)

Source: Reuters Health

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom